NYXH
Nyxoah S.A.NASDAQHealthcare$3.56+12.30%ClosedMarket Cap: $132.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.52
P/S
11.52
EV/EBITDA
-1.57
DCF Value
$-37.10
FCF Yield
-60.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.1%
Operating Margin
-844.4%
Net Margin
-899.1%
ROE
-135.3%
ROA
-131.8%
ROIC
-90.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.6M | 64.2% | $-19.7M | $-23.5M | $-0.59 | — |
| FY 2025 | $10.0M | 63.1% | $-84.7M | $-90.1M | $-2.37 | — |
| Q3 2025 | $2.0M | 60.5% | $-24.4M | $-23.6M | $-0.63 | — |
| Q2 2025 | $1.3M | 63.4% | $-19.9M | $-20.6M | $-0.55 | — |
| Q1 2025 | $1.1M | 61.8% | $-20.6M | $-22.4M | $-0.60 | — |
| Q4 2024 | $1.3M | 73.5% | $-18.3M | $-17.1M | $-0.46 | — |
| FY 2024 | $4.5M | 65.7% | $-58.8M | $-59.2M | $-1.81 | — |
| Q3 2024 | $1.3M | 61.9% | $-15.0M | $-17.1M | $-0.50 | — |
| Q2 2024 | $771.0K | 63.6% | $-13.3M | $-13.1M | $-0.43 | — |
| Q1 2024 | $1.2M | 62.7% | $-12.2M | $-11.9M | $-0.42 | — |
| Q4 2023 | $1.8M | 60.2% | $-10.8M | $-10.9M | $-0.38 | — |
| FY 2023 | $4.3M | 61.9% | $-45.1M | $-43.2M | $-1.55 | — |